Stocks and InvestingStocks and Investing
Fri, October 16, 2020
Thu, October 15, 2020
Wed, October 14, 2020
Tue, October 13, 2020

Jeffrey Hung Maintained (ACAD) at Buy with Increased Target to $57 on, Oct 13th, 2020


Published on 2024-10-27 14:20:12 - WOPRAI, Jeffrey Hung
  Print publication without navigation


Jeffrey Hung of Morgan Stanley, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $55 to $57 on, Oct 13th, 2020.

Jeffrey has made no other calls on ACAD in the last 4 months.



There are 7 other peers that have a rating on ACAD. Out of the 7 peers that are also analyzing ACAD, 1 agrees with Jeffrey's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $42 on, Tuesday, July 21st, 2020


These are the ratings of the 6 analyists that currently disagree with Jeffrey


  • Danielle Brill of "Raymond James" Initiated at Buy and Held Target at $65 on, Tuesday, August 25th, 2020
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $52 on, Thursday, August 6th, 2020
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $60 on, Thursday, August 6th, 2020
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $61 on, Tuesday, July 21st, 2020
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $55 on, Tuesday, July 21st, 2020
  • Paul Matteis of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $71 on, Tuesday, July 7th, 2020